Nasus Pharma (NYSE:NSRX) announced positive topline results from its Phase 2 clinical study of NS002, a proprietary intranasal epinephrine powder designed to treat life-threatening allergic reactions.
The study, which compared NS002 to the market-leading EpiPen® autoinjector in 50 healthy adults, demonstrated that the needle-free device delivered epinephrine into the bloodstream significantly faster and at higher concentrations during the critical first minutes of an emergency.
The data highlighted several pharmacokinetic advantages for NS002, powered by the company’s Nasax® powder platform.
On average, NS002 reached the critical therapeutic threshold of 100 pg/mL in just 1.69 minutes, compared to 3.42 minutes for the intramuscular EpiPen.
Perhaps more importantly for emergency outcomes, 67.4% of participants reached that threshold within 2.5 minutes using NS002, while only 27.1% reached it with the autoinjector.
By the 10-minute mark, approximately 95% of NS002 users had achieved therapeutic levels.
A key component of the study was the "nasal allergic challenge" (NAC), which simulated the congested or inflamed nasal conditions often present during an actual allergic reaction.
Even under these challenging conditions, NS002 maintained its speed and absorption advantages.
Total drug exposure (AUC) in the first 10 minutes was approximately 50% higher than the EpiPen, and peak concentrations (Cmax) remained comparable, ensuring the drug reached sufficient levels without over-exposure.